证券简称： 宏裕包材 证券代码： 837174 湖北省宜昌市夷陵区鸦鹊岭镇桔乡大道 1 号 湖北宏裕新型包材股份有限公司 Hubei Hongyu New Packaging Materials Co.,Ltd 湖北宏裕新型包材股份有限公司招股说明书（注册稿） 保荐机构（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主要 服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因素，审 慎作出投资决定。 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注 册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声 明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由发行人自 行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担股票依法发 ...

证券代码：600298 证券简称：安琪酵母 临 2023-050 号 安琪酵母股份有限公司 参加 2023 年湖北辖区上市公司投资者网上 集体接待日活动情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 安琪酵母股份有限公司（以下简称"公司"）于 2023 年 5 月 25 日（星期四）下午 14:30-16:35 在全景路演 （http://rs.p5w.net）网络平台通过网络文字互动方式参 加了 2023 年湖北辖区上市公司投资者网上集体接待日活动 （以下简称：投资者集体接待日活动）。 关于本次投资者集体接待日活动的召开事项，详见公司 于2023年5月19日在上海证券交易所网站（www.sse.com.cn） 上披露的《关于参加 2023 年湖北辖区上市公司投资者网上 集体接待日活动的公告》（临 2023-048 号）。现将参加活动 的情况公告如下： 一、投资者集体接待日活动情况 2023 年 5 月 25 日，公司董事会秘书高路、财务负责人 覃光新参加了投资者集体接待日活动，与投资者进行互动交 流和沟通 ...

证券简称： 宏裕包材 证券代码： 837174 湖北省宜昌市夷陵区鸦鹊岭镇桔乡大道 1 号 湖北宏裕新型包材股份有限公司 Hubei Hongyu New Packaging Materials Co.,Ltd 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律效 力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注 册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声 明均属虚假不实陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由发行人自 行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担股票依法发 行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 1-1-1 湖北宏裕新型包材股份有限公司招股说明书（申报稿） 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主 ...

证券代码：600298 证券简称：安琪酵母 临 2023-048 号 安琪酵母股份有限公司 关于参加 2023 年湖北辖区上市公司投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带责任。 重要内容提示： 召开时间：2023 年 5 月 25 日（星期四）14:30-16:35 召开地点：全景路演（http://rs.p5w.net）网络平 台 召开方式：网络文字互动 问题征集方式：投资者可于 2023 年 5 月 24 日（星 期三）17:00 前访问 https://ir.p5w.net/zj/，进入问题 征集专题页面，向本公司提出您关注的问题。 为进一步加强与投资者的互动交流工作，构建和谐投资 者关系，持续推动上市公司高质量发展，安琪酵母股份有限 公司（以下简称"公司"）将于 2023 年 5 月 25 日（星期四） 下午 14:30-16:35 参加由湖北证监局、湖北省上市公司协会、 深圳市全景网络有限公司联合举办的"提高发展质量 切实 回报股东"——2023 年湖北辖区上市公司投资者网上 ...

证券代码：600298 证券简称：安琪酵母 临 2023-047 号 安琪酵母股份有限公司 关于参加沪市食品饮料行业上市公司 2022 年度 暨 2023 年第一季度集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担个别及连带责任。 重要内容提示： 会议召开时间：2023 年 5 月 26 日（星期五）10:00-11:30 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 会议主题：沪市食品饮料行业上市公司集体业绩说明会 会议召开方式：上证路演中心视频直播和网络互动 问题征集方式：投资者可于 2023 年 5 月 19 日（星期五）至 5 月 25 日（星期四）16:00 前登录上证路演中心网站首页，进入沪 市食品饮料行业专场—公司页面，点击"提问预征集"栏目或通过 公司邮箱 gaolu@angelyeast.com 进行提问。公司将在说明会上对 投资者普遍关注的问题进行回答。 安琪酵母股份有限公司（以下简称"公司"）已于 2023 年 3 月31日和20 ...

Financial Performance - The company's operating revenue for Q1 2023 was RMB 3,396,542,504.36, representing a year-on-year increase of 12.03%[4] - The net profit attributable to shareholders for Q1 2023 was RMB 352,412,349.97, reflecting a 12.76% increase compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 330,332,192.23, which is a 24.77% increase year-on-year[4] - The net cash flow from operating activities for Q1 2023 was RMB 126,096,793.89, showing a significant increase of 140.35% compared to the previous year[4] - The basic earnings per share for Q1 2023 was RMB 0.4094, representing a year-on-year increase of 7.94%[4] - The weighted average return on equity for Q1 2023 was 3.74%, a decrease of 0.72 percentage points compared to the previous year[4] - The company reported a 55.62% decrease in financial expenses compared to the same period last year, primarily due to reduced interest expenses and exchange losses[10] - The total comprehensive income for Q1 2023 reached approximately ¥369.16 million, up from ¥316.92 million in Q1 2022, reflecting a growth of 16.4%[22] Assets and Liabilities - Total assets at the end of Q1 2023 amounted to RMB 17,514,338,451.13, an increase of 3.45% from the end of the previous year[5] - The equity attributable to shareholders at the end of Q1 2023 was RMB 9,634,594,520.08, which is a 4.07% increase from the end of the previous year[5] - Total liabilities for Q1 2023 were CNY 7,497,727,466.24, an increase from CNY 7,320,785,765.77 in Q1 2022[18] - The company's total equity increased to CNY 10,016,610,984.89 in Q1 2023, compared to CNY 9,608,842,954.14 in Q1 2022, reflecting a growth of 4.2%[18] Cash Flow - The net cash flow from operating activities for Q1 2023 was approximately ¥126.10 million, a significant improvement from a net outflow of ¥312.50 million in Q1 2022[23] - Cash inflow from operating activities in Q1 2023 was approximately ¥3.94 billion, a rise of 24.3% from ¥3.17 billion in Q1 2022[23] - Cash outflow from investing activities in Q1 2023 totaled approximately ¥525.31 million, compared to ¥442.63 million in Q1 2022, indicating an increase of 18.7%[24] - Cash inflow from financing activities in Q1 2023 was approximately ¥1.40 billion, down from ¥1.78 billion in Q1 2022, reflecting a decrease of 21.4%[24] - The net cash flow from financing activities for Q1 2023 was approximately ¥236.35 million, a decrease of 33.3% compared to ¥353.91 million in Q1 2022[24] Research and Development - Research and development efforts were increased, resulting in new product trials in yeast and food ingredients[14] - Research and development expenses for Q1 2023 amounted to CNY 130,301,728.62, an increase from CNY 119,850,888.67 in Q1 2022[21] - Research and development expenses increased to CNY 77,482,729.60 in Q1 2023, up from CNY 63,232,524.16 in Q1 2022, reflecting a growth of 22.6%[29] Market Strategy - The company focused on key regions and major clients for domestic market marketing, enhancing sales channels and service capabilities[14] - International market growth was supported by local employees in overseas subsidiaries, contributing to a positive growth trend[14] - The company intensified production organization to ensure full production capacity and improve product quality through process optimization[14] Compliance and Governance - The company is committed to compliance management and risk prevention measures to enhance internal governance and management efficiency[14] - The company did not apply new accounting standards or interpretations for the first quarter of 2023[33]

Financial Performance - The company's operating revenue for 2022 was approximately ¥12.84 billion, representing a year-over-year increase of 20.31% compared to ¥10.68 billion in 2021[16]. - The net profit attributable to shareholders for 2022 was approximately ¥1.32 billion, a slight increase of 0.97% from ¥1.31 billion in 2021[16]. - The net cash flow from operating activities decreased by 18.96% to approximately ¥1.07 billion in 2022, down from ¥1.32 billion in 2021[16]. - The total assets at the end of 2022 were approximately ¥16.93 billion, reflecting a year-over-year increase of 25.91% from ¥13.45 billion in 2021[16]. - The company's net assets attributable to shareholders increased by 35.06% to approximately ¥9.26 billion at the end of 2022, compared to ¥6.85 billion at the end of 2021[16]. - The basic earnings per share for 2022 was ¥1.5684, a decrease of 1.23% from ¥1.5879 in 2021[17]. - The weighted average return on equity for 2022 was 16.47%, down 4.07 percentage points from 20.54% in 2021[17]. - The company reported a total of ¥3.86 billion in revenue for Q4 2022, with a net profit attributable to shareholders of approximately ¥424.15 million[18]. Dividend Distribution - The company reported an undistributed profit of RMB 6,176,161,296.18 as of the end of 2022, with a proposed cash dividend of RMB 5 per 10 shares, totaling an expected distribution of RMB 434,416,439.50[4]. - The total share capital for the dividend distribution is based on 868,832,879 shares after excluding 136,000 shares for repurchased restricted stock[4]. - The cash dividend amount (including tax) for the year is 434,416,439.50 RMB, representing 32.88% of the net profit attributable to ordinary shareholders[118]. Audit and Compliance - The company received a standard unqualified audit report from Da Xin Accounting Firm[3]. - The company’s financial report is guaranteed to be true, accurate, and complete by its responsible personnel[3]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[5]. - The company has not experienced any violations of decision-making procedures regarding external guarantees[5]. - The company has not disclosed any significant changes in its board of directors or supervisory board members[3]. - The audit report emphasizes the importance of evaluating the appropriateness of accounting policies and estimates made by management[196]. - The audit concluded that there were no significant inconsistencies in the other information provided in the annual report compared to the financial statements[193]. Market and Operational Strategy - The company aims to become the "global number one yeast enterprise and an international first-class biotechnology company," focusing on innovation and addressing challenges such as rising costs and supply chain pressures[21]. - The company operates under the stock code 600298 on the Shanghai Stock Exchange[14]. - The company has established a digital transformation strategy, enhancing its digital operational capabilities significantly[32]. - The company is the second largest yeast company globally and has established a comprehensive technology and equipment system for the yeast industry in China[26]. - The company has a total fermentation capacity of 350,000 tons, with a domestic market share of 55% and a global market share exceeding 15%[27]. - The company is actively expanding its market presence through strategic partnerships and investments in technology[85]. Research and Development - The company has filed 324 invention patents and completed 78 national and provincial-level research projects[30]. - The company's R&D expenditure totaled ¥536,125,044.14, accounting for 4.17% of total revenue[51]. - Research and development expenses increased by 12.82% to ¥536,125,044.14, compared to ¥475,198,935.51 last year[36]. - The company is committed to enhancing its R&D capabilities to drive technological innovation in the yeast industry[71]. Environmental Responsibility - The company invested approximately 534.88 million yuan in environmental protection during the reporting period[128]. - The company maintained compliance with pollution discharge standards across all major subsidiaries, with all reported emissions meeting the required limits[129]. - The company successfully reduced carbon emissions by 153,000 tons through various measures, including the use of clean energy and carbon reduction technologies[140]. - The company has implemented a comprehensive environmental self-monitoring plan, ensuring real-time monitoring of wastewater and air emissions[135]. Governance and Management - Independent directors constitute more than 50% of the board, exceeding regulatory requirements, contributing positively to decision-making[73]. - The company has established a fair and transparent performance evaluation and incentive mechanism for directors and senior management[73]. - The company emphasizes cooperation with stakeholders, including banks and employees, to promote sustainable development[73]. - The company has implemented a cumulative voting system for director elections, enhancing governance transparency[74]. Shareholder Structure and Capital Management - The total number of shares held by the chairman and general manager remained unchanged at 0 shares[82]. - The total pre-tax remuneration for the general manager was 84.76 million CNY, while the deputy general manager received 203.08 million CNY[82]. - The company issued 36,651,936 new shares during the non-public offering, increasing total share capital to 869,344,879 shares[171]. - The company’s total share capital increased from 832,692,943 shares to 869,344,879 shares following the issuance of new shares[176]. Future Outlook - The company aims to achieve a sales revenue target of RMB 143.9 billion in 2023, with a net profit growth of 10.21% year-on-year[69]. - The company plans to reach a revenue target of RMB 20 billion by 2025, focusing on yeast and biotechnology sectors[68]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[87]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[88].

Financial Performance - The company's operating revenue for the first half of 2022 reached ¥6,090,362,514.97, representing a 16.36% increase compared to ¥5,233,898,313.88 in the same period last year[14]. - The net profit attributable to shareholders of the listed company was ¥667,800,676.33, a decrease of 19.33% from ¥827,820,623.63 in the previous year[14]. - Basic earnings per share decreased by 18.47% to ¥0.8104 from ¥0.9939 in the same period last year[17]. - The weighted average return on net assets decreased by 3.99 percentage points to 9.29% from 13.28% in the previous year[17]. - The company reported a non-recurring gain of ¥72,380,425.86 for the current period, after accounting for tax and minority interests[19]. - The company achieved a revenue of 6.09 billion CNY, representing a year-on-year growth of 16.36%[30]. - The net profit attributable to shareholders decreased by 19.33% to 668 million CNY, with basic earnings per share dropping by 18.47% to 0.8104 CNY[30]. - The company's comprehensive income totalled approximately ¥680.86 million for the first half of 2022, compared to ¥840.85 million in the first half of 2021, indicating a decrease of 19%[118]. Cash Flow and Investments - The net cash flow from operating activities was -¥262,611,082.27, worsening by 31.50% compared to -¥199,701,296.34 in the same period last year[14]. - The net cash flow from investment activities decreased by 76.70%, amounting to approximately ¥1.00 billion, primarily due to increased project payments[35]. - The net cash flow from financing activities surged by 369.23% to approximately ¥1.90 billion, mainly from funds raised through a private placement[35]. - The company reported a net cash inflow from operating activities of CNY 293,255,822.93, a decrease of 47.5% compared to CNY 559,316,789.78 in the same period last year[121]. - The company experienced a net cash outflow from investment activities of CNY 1,004,061,197.21, compared to a net outflow of CNY 568,222,376.93 in the prior year, indicating a significant increase in investment expenditures[120]. Assets and Liabilities - The total assets of the company increased by 20.02% to ¥16,137,683,759.07 from ¥13,445,647,466.86 at the end of the previous year[16]. - The total liabilities reached CNY 7,240,122,977.63, compared to CNY 6,244,622,116.15, showing an increase of about 16%[106]. - The company's total equity at the end of the reporting period was 6,840,794,152.37 RMB, reflecting an increase from the previous period[132]. - The capital reserve increased by 1,411,954,858.91 RMB during the first half of 2022, indicating strong financial health[133]. - The company’s total assets at the end of the reporting period were 6,187,901,777.44 RMB, reflecting growth in asset management[128]. Production and Capacity - The company has a total yeast production capacity of 350,000 tons across 16 factories located in various regions including Hubei, Guangxi, and Egypt[20]. - The production capacity utilization rate for yeast fermentation reached 102%, with a total output of 168,000 tons in the first half of the year[32]. - The company launched 108 new products in the first half of 2022, including 21 health food products and 6 new invention patents[32]. - The company plans to expand its production capacity with projects in Russia and Egypt, targeting annual production capacities of 8,000 tons and 20,000 tons of yeast products, respectively[51]. Market and Sales - The company operates a global marketing network with 13 domestic sales organizations and 6 overseas divisions, selling products in 163 countries[21]. - The company exports products to 163 countries and regions, with over 95% of overseas sales being self-owned brands[29]. - The international market is growing faster than the domestic market, with significant growth in microbial nutrition, plant protection, and yeast extract businesses[31]. - The company is actively expanding its international presence by registering overseas marketing subsidiaries and hiring local sales personnel[31]. Research and Development - The company has established 46 innovation platforms and has been awarded over 240 patents, demonstrating its commitment to technological innovation[27]. - Research and development expenses rose by 31.74% to approximately ¥284.47 million, driven by increased R&D efforts and personnel[35]. - The company focuses on research and development in biotechnology and health management services, indicating a commitment to innovation[142]. Environmental Compliance - The company has maintained compliance with environmental standards, with all monitored pollutants meeting regulatory limits[61]. - The total actual emissions for the first half of 2022 were significantly below the permitted limits, indicating effective pollution control measures[62]. - The company’s environmental protection measures have been recognized, with all wastewater discharge points meeting the required standards[61]. - The company has implemented a real-time monitoring system for wastewater and air emissions, ensuring compliance with regulatory standards[67]. Corporate Governance - The company has undergone changes in its board and management personnel, with new appointments and elections following the annual shareholder meeting[54]. - The new board of directors and management team were appointed on April 18, 2022, with a term lasting until April 18, 2025[55]. - The company has not implemented any employee stock ownership plans or other incentive measures in the first half of 2022[59]. Shareholder Information - The total number of common shareholders reached 67,051 by the end of the reporting period[96]. - The largest shareholder, Hubei Angel Biotechnology Group Co., Ltd., held 330,482,045 shares, accounting for 38.02% of total shares[97]. - The company completed a non-public offering of 36,651,936 shares, increasing the total shares from 832,692,943 to 869,344,879[139]. Risk Management - The company faces increased market competition in the yeast industry, with a focus on strengthening market control and adjusting sales strategies to mitigate risks[48]. - The company is experiencing rising raw material costs, particularly for molasses, which has led to a significant increase in production costs[48]. - The company is enhancing its international trade and exchange rate policy research to mitigate foreign exchange risks related to export activities[48].